Sufentanil limits the myocardial infarct size by preservation of the phosphorylated connexin 43.
Sufentanil, with a potent analgesia effect, has been wildly used in anesthesia and analgesia, especially for the cardiovascular surgeries. The aim of the study was to evaluate whether sufentanil provides cardioprotection and the effect of connexin 43 on the cardiac infarct size reduction. Sufentanil post-conditioning (bolus injection at 0.1, 0.3, 1, 3, 10 μg/kg) or ischemic post-conditioning (3 cycles of a 10s reperfusion alternating with a 10s ischemia) was induced in an intact rat heart model of ischemia-reperfusion injury. Both ischemic and sufentanil post-conditioning reduced the myocardial infarct size compared with control group. The infarct size limitation of sufentanil was dose-dependent, 1 μg/kg has the optimal effect and increasing dosage could not afford further cardioprotection. Connexin 43 underwent dephosphorylation in response to ischemia-reperfusion measured by Western blot at the anterior myocardium tissues of left ventricle while sufentanil preserved the phosphorylation of connexin 43. The results demonstrated that sufentanil limits myocardial infarct size which is similar with ischemic post-conditioning at the dosage of 1 μg/kg. Preservation of phosphorylation of connexin 43 plays an important role in the cardioprotection of ischemic and sufentanil post-conditioning.